-
-
-
-
-
-
-
Ionis licenses zilganersen to Recordati for ex-U.S. markets
-
-
-
-
-
-
-
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
-
-
-
-
-
-
-
FDA grants priority review to Ionis' Alexander disease treatment
-
-
-
-
-
-
-
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
-
-
-
-
-
-
-
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
-
-
-
-
-
-
-
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
-
-
-
-
-
-
-
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
-
15,713 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

